Pavel Balabanov retweeted
📢The CHMP recommends authorising a new treatment for early #AlzheimersDisease in the EU.
Leqembi is intended for treatment of mild dementia and cognitive impairment in a restricted patient population with a specific genetic make-up.
👉 ema.europa.eu/en/news/leqemb…
To gather input for our revised guideline for treatment of epileptic disorders, we will organize a one-day workshop -29 Jan 2024. More info here: europa.eu/!qHYNBc
33
To address the topic of effective and safe use of #psychedelics we are holding a multi-stakeholder workshop – "Towards an EU regulatory framework for psychedelics". Check out the agenda and the topics here: europa.eu/!xMpqMf
1
51
EMA will host a Multi-stakeholder workshop on the guideline on clinical investigation of medicinal products in the treatment of epileptic disorders | European Medicines Agency europa.eu/!tTgDFr via @EMA_News
Date:29/01/2024
Location:Online
Our Guideline on Clinical investigation of medicinal products in the treatment of depression just published here: europa.eu/!yW6dYK via @EMA_News
1
27
What are the challenges and opportunities that #psychedelics present as potential treatments in #mentalhealth disorders: see the position of KOLs in #regulatory #neuroscience in this collaborative work thelancet.com/journals/lance…
2
113
On the World Duchenne awareness day #WDAD2022 let's remember that only by working together we can hope to find a brighter future. Share the word. Raise awareness.
Pavel Balabanov retweeted
EMA started the evaluation of applications for adapted versions of Comirnaty and Spikevax. #COVID19vaccines
Pavel Balabanov retweeted
If taken in the first days of COVID symptoms appearing, the new antiviral drug could reduce hospitalisations and death in at-risk people by 90 per cent, according to its maker.
Better still, it's taken orally with water. 🚰
Read more 👇
euronews.com/next/2022/01/27…
Pavel Balabanov retweeted
EMA recommends authorising the oral antiviral #Paxlovid for treating #COVID19 in adults who do not require supplemental oxygen and who are at increased risk of severe disease.
👉ema.europa.eu/en/news/covid-…
Pavel Balabanov retweeted
EMA recommends granting a marketing authorisation in the 🇪🇺 for Trodelvy, a first-in-class #medicine to treat an aggressive form of #breastcancer: ema.europa.eu/en/news/first-…
Pavel Balabanov retweeted
EMA has published the clinical data supporting the conditional marketing authorisation of Vaxzevria, previously #COVID19Vaccine AstraZeneca.
ema.europa.eu/en/human-regul…
#ClinicalData
Visit clinicaldata.ema.europa.eu/w…
Pavel Balabanov retweeted
It seems that the 4 vaccines authorised in the EU 🇪🇺 protect against all strains, including the delta variant. First real-world data suggest that:
➡️2 doses of vaccines protect against the delta variant
➡️antibodies from the approved vaccines neutralise this variant. #EMAPresser
Pavel Balabanov retweeted
EMA’s human medicines committee (#CHMP) recommends 8 #medicines for approval at its May 2021 meeting:https://teapawt.org/t.co/Rp8Oy7p2c0
Pavel Balabanov retweeted
EMA is monitoring very closely the data on the Indian variant. We are seeing promising evidence that mRNA vaccines would be able to neutralise this variant. #EMAPresser
Pavel Balabanov retweeted
EMA has started a rolling review of data on sotrovimab (also known as VIR-7831 and GSK4182136) a monoclonal antibody developed by GlaxoSmithKline and Vir Biotechnology, for the treatment of #COVID19.
Follow the announcement here:https://teapawt.org/t.co/CqQNl6A4g3
Pavel Balabanov retweeted
EMA’s safety committee (#PRAC) is continuing its evaluation of very rare cases of unusual blood clots in people vaccinated with the AstraZeneca#COVID19 vaccine
👉 https://teapawt.org/t.co/7fEBLZkMC5
#COVID19Vaccines #medicine
EMA: COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets | European Medicines Agency europa.eu/!fK84jk via @EMA_News
Pavel Balabanov retweeted
The vaccine from Janssen-Cilag International N.V. is currently under rolling review. A date for submission of a marketing authorisation application has not been confirmed. As we have done for all #COVID19vaccines, we will communicate once such application is received.
Pavel Balabanov retweeted
After having received more data from the company, EMA is expecting Astra Zeneca to submit a conditional marketing application for its #COVID19vaccine next week. Possible conclusion - end of Jan, depending on data and evaluation progress. #EMAPublicMeeting2






